Last updated on April 20, 2014 at 8:28 EDT

Latest Alethia Biotherapeutics Inc. Stories

2013-10-01 16:25:41

PLANTATION, Fla. and MONTREAL, Oct. 1, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. announced that Alethia Biotherapeutics Inc., a privately held biotechnology company focusing on the development of therapeutic monoclonal antibodies, has contracted for the next phase of manufacturing activities for two of their leading drug candidates: -- AB-16B5, a monoclonal antibody which targets secreted clusterin for the inhibition of cancer-associated epithelial-to-mesenchymal...

2011-06-02 09:00:00

PLANTATION, Fla. and MONTREAL, June 2, 2011 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI), a full service CMO focused on process development and GMP manufacturing of cell culture derived biopharmaceuticals, and Alethia Biotherapeutics, Inc., a biotechnology company focused on monoclonal antibody development with a very sensitive and highly disease-tissue specific proprietary target discovery platform, announced a collaboration on the development of a mammalian cell line-based IgG...